- Eurofins Companies Across the World Develop New Solutions to Support Health Authorities Monitoring the Hantavirus Outbreak
May 14, 2026
LUXEMBOURG, May 14, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins (Paris:ERF) companies are actively monitoring the hantavirus outbreak, and developments related to the Andes strain. As of 12 May, a total of 11 hantavirus cases, including 3 deaths, associated with a cruise ship outbreak had been reported. While the World Health Organization has stated that more cases of the virus are expected it has also indicated that "there is no sign that we are seeing the start of a larger outbreak".1
Eurofins companies already have a well-established testing offering for the detection of Hantavirus in many countries. Eurofins laboratories around the world have the capabilities to respond to testing needs with the development of new tests and methods, which are subject to regulation and requirements dependent on the country in which a Eurofins laboratory operates in.
In the U.S, Eurofins Viracor can rapidly develop and validate both quantitative real-time PCR and next generation sequencing (NGS) based molecular detection assays for hantavirus. An NGS assay is currently under development in which known respiratory pathogens, including all hantavirus strains. While no Emergency Use Authorization (EUA) has yet been issued for a molecular test for hantavirus detection by the US Food and Drug Administration, Eurofins Viracor is closely monitoring the situation, and would look to use in vitro transcribed RNA for test validation purposes, Eurofins Viracor applied this approach for SARS-CoV-2 testing in 2020 prior to the availability of known positive samples.
Eurofins Clinical Diagnostic Spain currently has the diagnostic capability to study Hantavirus, including the detection of the Andes strain, using both serological and molecular techniques. Appropriate clinical samples are analysed using a molecular biology technique based on molecular hybridisation with PCR amplification, allowing for the direct detection of Hantavirus.
Eurofins Biomnis, located in France, has significant experience in facilitating testing to detect 6 common strains of Hantavirus (5 from Europe and Asia, and 1 from America), and partner with the French reference centre (CNR) as a screening laboratory for Hantavirus testing. These tests have not been developed to specifically detect the Andes strain. In France, establishing a test to detect the Hantavirus Andes strain would require sample possession and would be subject to authorisation by ANSM (French National Agency for Medicines and Health Products Safety).
Gold Standard Diagnostics Frankfurt GmbH offers the NovaLisa Hantavirus IgG and IgM ELISA assays to detect antibodies against Hantavirus in human serum or plasma, returning results in 2 hours. These tests have been developed with the German reference centre for Hantavirus, Konsiliarlabor für Hantaviren, part of the Robert Koch-Institut, Berlin. For veterinary, diagnostics Gold Standard Diagnostics offers assays, including VetBlot Hantavirus, a LineBlot for the qualitative determination of IgG antibodies against Hantavirus in veterinary serum.
Story Continues
Eurofins companies have a proven track record and expertise in responding to global or acute health epidemics and crises and will actively monitor the development of the outbreak.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With over 65,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
1https://x.com/WHO/status/2054207705452020119
View source version on businesswire.com: https://www.businesswire.com/news/home/20260513231616/en/
Contacts
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
View Comments
- Eurofins Scientific SE: Director/PDMR Shareholding
May 11, 2026
LUXEMBOURG, May 11, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Sean Murray 2. Reason for the notification a) Position / status EVP, Life Testing North America b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 61.54 EUR 61,538 d) Aggregated information — Aggregated volume 1000 — Price EUR 61,538 e) Date of the transaction 2026-05-07 f) Place of the transaction XPAR
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260511617242/en/
Contacts
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
View Comments
- Eurofins Scientific SE: Weekly Report on Share Repurchases From 04th May to 08th May 2026
May 11, 2026
LUXEMBOURG, May 11, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 45 000 57.9715 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 15 000 57.9946 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 05/05/2026 FR0014000MR3 45 000 58.5531 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 05/05/2026 FR0014000MR3 15 000 58.5520 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 06/05/2026 FR0014000MR3 45 000 60.2065 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 06/05/2026 FR0014000MR3 15 000 60.2423 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 07/05/2026 FR0014000MR3 40 000 59.9996 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 07/05/2026 FR0014000MR3 20 000 60.0521 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 08/05/2026 FR0014000MR3 20 000 59.2439 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 08/05/2026 FR0014000MR3 36 000 59.2474 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 08/05/2026 FR0014000MR3 2 000 59.2057 AQEU EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 08/05/2026 FR0014000MR3 2 000 59.1924 TQEX TOTAL 300 000 59.2011
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes
View source version on businesswire.com: https://www.businesswire.com/news/home/20260511670244/en/
Contacts
Eurofins Scientific SE
View Comments
- Is Eurofins Scientific (ENXTPA:ERF) Attractively Priced After Recent Share Price Weakness?
May 9, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Wondering if Eurofins Scientific at €59.34 is offering good value right now, or if the recent price leaves limited upside? This article breaks down what the current market price might be implying. The stock is up 0.5% over the last week, while the 30 day return is a 9.1% decline and the year to date return is a 4.3% decline. This is set against a 6.6% gain over the past year and 4.1% over three years, but a 22.8% decline over five years. Recent coverage has focused on Eurofins Scientific as a key player in life sciences testing and diagnostics. This includes commentary on how the business model fits into long term demand for laboratory services, adding context for investors watching how sentiment around the stock shifts over time. Eurofins Scientific currently has a valuation score of 5/6. The next sections will compare what different valuation methods say about that score and will point to an even more useful way to think about value that will be covered at the end.
Eurofins Scientific delivered 6.6% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.
Approach 1: Eurofins Scientific Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today to reflect risk and the time value of money.
For Eurofins Scientific, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The last twelve months Free Cash Flow is €726.5 million. Analyst estimates are available for the next few years and Simply Wall St extrapolates beyond that, with projected Free Cash Flow of €1,486.0 million in 2030 and further annual figures through 2035.
Bringing all those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of €196.54 per share. Compared with the current share price of €59.34, this implies the stock is 69.8% undervalued according to this method.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Eurofins Scientific is undervalued by 69.8%. Track this in your watchlist or portfolio, or discover 227 more high quality undervalued stocks.ERF Discounted Cash Flow as at May 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eurofins Scientific.
Approach 2: Eurofins Scientific Price vs Earnings
For profitable companies, the P/E ratio is a useful way to see how much you are paying for each euro of current earnings. A higher or lower P/E often reflects what the market is pricing in for growth and risk, with faster growth and lower perceived risk usually supporting a higher “normal” or “fair” P/E.
Story Continues
Eurofins Scientific currently trades on a P/E of 25.1x. This stands below the Life Sciences industry average of 36.5x and also below the peer group average of 30.9x, suggesting the stock is priced more conservatively than many comparable companies on this simple metric.
Simply Wall St’s Fair Ratio for Eurofins Scientific is 19.7x. This is a proprietary estimate of what the P/E might be, given factors such as earnings growth, industry, profit margin, market cap and specific risks. Because it is tailored to the company’s own profile, the Fair Ratio can be more informative than a straight comparison with broad industry or peer averages.
With the current P/E of 25.1x sitting above the Fair Ratio of 19.7x, the stock appears expensive relative to this company specific yardstick.
Result: OVERVALUEDENXTPA:ERF P/E Ratio as at May 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 99 top founder-led companies.
Upgrade Your Decision Making: Choose your Eurofins Scientific Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your way of attaching a clear story about Eurofins Scientific to concrete numbers like fair value, and assumptions for future revenue, earnings and margins, so that the company’s story, the forecast, and the fair value all line up in one place on Simply Wall St’s Community page, which is used by millions of investors, and then update automatically as fresh news or earnings arrive, helping you compare fair value with the current price and decide if Eurofins Scientific at €59.34 looks closer to a higher fair value such as €93.0 or to a lower fair value such as €46.0 based on the narrative you find most convincing.
For Eurofins Scientific however we will make it really easy for you with previews of two leading Eurofins Scientific Narratives:
🐂 Eurofins Scientific Bull Case
Fair value in this bullish narrative: €93.00
Implied undervaluation versus €59.34: 36.2%
Revenue growth assumption: 8.9%
Views Eurofins Scientific as benefiting from digital and infrastructure investment, with efficiency gains and higher margins already feeding into analyst assumptions. Sees growth coming from advanced testing demand and specialty areas such as genomics and advanced diagnostics, with analysts using this to support higher earnings and free cash flow expectations. Anchors a €93.00 fair value on assumptions for stronger revenue, higher profit margins and a future P/E that is below where the wider Life Sciences group is currently referenced in the narrative.
🐻 Eurofins Scientific Bear Case
Fair value in this bearish narrative: €48.00
Implied overvaluation versus €59.34: 23.1%
Revenue growth assumption: 4.9%
Highlights risks from automation, client insourcing and tighter regulation that could weigh on Eurofins Scientific's traditional lab activities and margins. Flags concerns that ongoing expansion and acquisitions may leave the company with underused assets, higher integration costs and weaker pricing power against large clients. Uses more cautious assumptions on revenue growth, margins and a lower future P/E to arrive at a €48.00 fair value that sits well below the current share price in this scenario.
Having both narratives side by side lets you decide which set of assumptions feels closer to how you see Eurofins Scientific's future, and whether the current price around €59.34 fits better with the higher or lower fair value story in your own portfolio context.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eurofins Scientific on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Do you think there's more to the story for Eurofins Scientific? Head over to our Community to see what others are saying!ENXTPA:ERF 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ERF.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2026
May 7, 2026
LUXEMBOURG, May 07, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
ANNEXE B
Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF)
EUROFINS SCIENTIFIC SE – E1013
2. Identity of the notifier (if another person makes the notification on behalf of the issuer)
N/A
3. Total number of shares composing the share capital of the notifying issuer
176,000,000
4. Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rightsii
364,805,539
5. Origin of the changeiii
Reduction in numbers of voting rights:
Cancellation of some class A beneficiary units Purchase of treasury shares as part of the Company’s share buyback programme
6. Date when the change occurred
30 April 2026
i Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.
ii For further details on the total number of voting rights, please refer to point 1(b) of circular CSSF 08/349.
iii As, for example, a capital increase or reduction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507828783/en/
Contacts
Eurofins Scientific SE
View Comments
- Eurofins Scientific SE: Weekly Report on Share Repurchases from 27th April to 30th April 2026
May 4, 2026
LUXEMBOURG, May 04, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 27/04/2026 FR0014000MR3 35 000 62.5188 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 27/04/2026 FR0014000MR3 5 000 62.3938 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 28/04/2026 FR0014000MR3 5 000 60.3208 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 28/04/2026 FR0014000MR3 35 000 60.3662 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 29/04/2026 FR0014000MR3 45 000 58.6681 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 29/04/2026 FR0014000MR3 15 000 58.5297 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 30/04/2026 FR0014000MR3 17 000 57.9023 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 30/04/2026 FR0014000MR3 53 000 57.8054 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 30/04/2026 FR0014000MR3 3 000 57.9070 AQEU EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 30/04/2026 FR0014000MR3 2 000 57.9029 TQEX TOTAL 215 000 59.3959
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504167264/en/
Contacts
Eurofins Scientific SE
View Comments
- UL Solutions (ULS) to Acquire Eurofins Scientific’s E&E Business for ~$670M
May 1, 2026
UL Solutions Inc. (NYSE:ULS) is one of the best IPO stocks to buy in 2026. On April 13, UL Solutions entered into a definitive agreement to acquire the Electrical & Electronics/E&E business of Eurofins Scientific for an enterprise value of ~€575 million ($670 million). The deal includes the well-known MET Labs certification mark and is designed to expand UL Solutions’ global laboratory footprint, particularly in the EMEA and Asia-Pacific regions.
The acquisition is expected to close in Q4 2026, pending regulatory approvals. The acquisition strengthens UL Solutions’ position in the testing, inspection, and certification/TIC industry, specifically for wireless testing, electromagnetic compatibility, and medical devices. The Eurofins E&E business is projected to generate ~$200 million in revenue in 2026. UL Solutions expects the transaction to be accretive to its adjusted diluted EPS within the first full calendar year following the close, supported by anticipated cost synergies to be realized over 3 years.UL Solutions (ULS) to Acquire Eurofins Scientific’s E&E Business for ~$670M
Financing for the deal will be a mix of cash on hand and the company’s undrawn credit facility. Notably, about 30% of the purchase price will be covered by proceeds from the recent sale of UL Solutions Inc.’s (NYSE:ULS) Employee Health and Safety software business, which was finalized on April 1. This move aligns with the company’s strategic focus on its core TIC and Risk & Compliance capabilities.
UL Solutions Inc. (NYSE:ULS) is a global leader in applied safety science. It provides testing, inspection, and certification services, along with software and advisory solutions, to help businesses in over 110 countries manage regulatory compliance and product innovation.
While we acknowledge the potential of ULS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Eurofins Scientific: Director/PDMR Shareholding
Apr 27, 2026
LUXEMBOURG, April 27, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Sean Murray 2. Reason for the notification a) Position / status EVP, Life Testing North America b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 62.59 EUR 43,810 d) Aggregated information — Aggregated volume 700 — Price EUR 43,810 e) Date of the transaction 2026-04-23 f) Place of the transaction XPAR
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260427774630/en/
Contacts
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
View Comments
- Eurofins Scientific SE: Weekly Report on Share Repurchases from 23rd April to 24th April 2026
Apr 27, 2026
LUXEMBOURG, April 27, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 40 000 61.8744 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 10 000 61.9124 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 24/04/2026 FR0014000MR3 5 000 62.4335 CEUX EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 24/04/2026 FR0014000MR3 35 000 62.3608 XPAR TOTAL 90 000 62.0988
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes
View source version on businesswire.com: https://www.businesswire.com/news/home/20260427550178/en/
Contacts
Eurofins Scientific SE
View Comments
- Eurofins Launches Seventh Buy-Back Programme of Its Own Shares
Apr 24, 2026
LUXEMBOURG, April 24, 2026--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (the "Company") (EUFI.PA) (Paris:ERF) announces its intention to launch a new buy-back programme of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 4.5% of its share capital. The maximum amount meant for the repurchase of the Company’s shares may not exceed a sum corresponding to an amount equivalent to the value of 4.5% of the shares composing the share capital of the Company as of the Board of Directors Meeting Date, on 23 April 2026. This seventh programme follows the sixth programme that took place between 25 April 2025 and 23 April 2026. The new programme is commencing on 24 April 2026 and will last until 23 April 2027 at the latest. The Company may at any time interrupt this programme in view of market conditions and/or the evolution of its investment strategy.
The shares to be purchased under this programme will be used to hedge the Company’s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorisation of the AGM held on 23 April 2026.
The Company is mandating an independent provider of financial services to execute the first tranche of this programme starting on 24 April 2026 and ending on 23 June 2026 with a maximum volume of 7,920,000 shares or 4.5% of its current share capital.
In addition to conducting share repurchases on regulated markets (limited to 25% of the average daily trading volume of shares over the past 20 trading days on the regulated markets where purchases are made), the independent provider of financial services is also authorised to purchase blocks of shares on the open market. Considering both shares repurchased on regulated markets as well as block purchases, the total amount of shares repurchased on any trading day cannot exceed 50% of the average daily trading volume of shares over the past 20 trading days on regulated markets.
Over the course of the sixth share buy-back programme, 5,116,661 shares were repurchased, representing 2.91% of the current share capital.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
Story Continues
With over 65,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260424615798/en/
Contacts
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
View Comments
